Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naive Prostate Cancer in Japanese Men.

ABSTRACT:

Background

Treatment strategies have changed dramatically in recent years with the development of a variety of agents for metastatic hormone-naïve prostate cancer (mHNPC). There is a need to identify prognostic factors for the appropriate choice of treatment for patients with mHNPC, and we retrospectively examined these factors.

Methods

Patients with mHNPC treated at our institution from 2000 to 2019 were included in this study. Overall survival (OS) was estimated retrospectively using the Kaplan-Meier method, and factors associated with OS were identified using univariate and multivariate analyses. A prognostic model was then developed based on the factors identified. Follow-up was terminated on 24 October 2021.

Results

The median follow-up duration was 44.2 months,

SUBMITTER: Nakagawa R 

PROVIDER: S-EPMC9563582 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature